Industry-Sponsored Satellite Symposia

Fibrosis, Flares, and Forward Thinking in Inflammatory Bowel Disease Care: Unlocking the TL1A Axis

Bruce E. Sands, MD, MS, FACG, Jordan E. Axelrad, MD, MPH, FACG and Millie D. Long, MD, MPH, FACG
5:30 pm – 7:30 pm • Renaissance Phoenix Downtown - South Ballroom

Managing moderate to severe inflammatory bowel disease (IBD) requires more than symptom relief—it demands a treat-to-target approach focusing on clinical remission, healing, and quality of life. Join this live PeerView Talks event to explore how targeting TL1A with monoclonal antibodies offers promising new strategies to improve outcomes, address fibrosis, and achieve deep remission in IBD patients.

This program is supported by educational grants from Genentech, a member of the Roche Group and Merck & Co., Inc.

Decision Points in the Management of GERD: A Virtual Patient Simulation

Charles P. Vega, MD, Prakash Gyawali, MD, FRCP, FACG and Rena H. Yadlapati, MD, MSHS, FACG
5:30 pm – 7:30 pm • Sheraton Phoenix Downtown - Phoenix Ballroom A

Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal (GI) disorders seen in GI practices. Using patient case simulations, expert faculty will help learners navigate the complexities of GERD diagnosis and management. Learners will be able to select tests and treatments in real time while faculty provide feedback and guidance supported by the latest clinical evidence. This engaging and interactive patient simulation symposium will help to advance clinicians’ clinical decision-making skills in managing GERD patients in their practices.

This program is supported by an independent educational grant from Phathom Pharmaceuticals.

Stop Spinning Your Wheels on EoE!

Evan S. Dellon, MD, MPH, FACG and George Dickstein, MD
7:30 pm – 9:30 pm • Sheraton Phoenix Downtown - Paradise Valley Room

Join our experts, Dr. Evan Dellon and Dr. George Dickstein, in a live, interactive dinner program to test your knowledge and deepen your understanding of eosinophilic esophagitis (EoE) based on the latest science.

This program is sponsored by Sanofi and Regeneron.

Constipation Clash: An IBS-C Challenge

Lin Chang, MD , FACG, Baharak Moshiree, MD, MSc, FACG and Charles P. Vega, MD
7:30 pm – 9:30 pm • Sheraton Phoenix Downtown - Phoenix Ballroom B

Irritable bowel syndrome with constipation (IBS-C), a chronic and often debilitating condition, continues to pose diagnostic and therapeutic challenges to clinicians and patients. Please join us for an interactive, “faculty feud”-style educational program designed to improve the diagnosis and treatment of IBS-C to improve patient outcomes and quality of life. Faculty-led teams will go head-to-head, identifying the most popular answer to survey-based questions. Distinguishing features, diagnostic criteria, symptoms burden, and evidence-based management, including first line and prescription treatment options for IBS-C will be discussed.

This program is supported by an independent educational grant from Ardelyx.

The MASH Game Show: From Risk Stratification to Patient Identification

Mazen Noureddin, MD, MHSc, Naim Alkhouri, MD and Nadege T. Gunn, MD
7:30 pm - 9:30 pm • Sheraton Phoenix Downtown - Phoenix Ballroom A

Metabolic dysfunction-associated steatohepatitis (MASH) is a growing global health problem. Patients with MASH are often underdiagnosed, and thus they may not be benefiting from newly approved therapies that can alter the disease course. In this engaging, fast paced, game show-style symposium, compete against your colleagues as you learn critical information from expert faculty about noninvasive testing for MASH, risk stratification, treatment selection and monitoring, and other important topics. Test your knowledge about the latest clinical evidence and best practices for MASH treatment, including new therapies and those in late-stage clinical development. Put on your thinking caps and join us for The MASH Game Show!

This program is supported by an independent educational grant from Madrigal Pharmaceuticals.

Ulcerative Colitis Management: Raising Expectations

David T. Rubin, MD, FACG and Millie D. Long, MD, MPH, FACG
7:30 pm – 9:00 pm • Sheraton Phoenix Downtown - Phoenix Ballroom D

Join Dr. David T. Rubin and Dr. Millie D. Long for an engaging exploration of the evolving landscape of ulcerative colitis (UC) management. This interactive, case-based session will discuss advancements in UC care, integrating the updated ACG 2025 guidelines and their application in treatment strategies. Our experts will review the long-term efficacy and safety data for IL-23p19 inhibitors. We look forward to seeing you there!

This program is sponsored by Eli Lilly and Company.

From Pathways to Practice: Exploring IL-23 Inhibitors for Inflammatory Bowel Disease

David T. Rubin, MD, FACG, Jessica R. Allegretti, MD, MPH, FACG, Jamie T. Brogan, BA, MS, FNP-BC and Corey A. Siegel, MD, MS
7:00 pm - 9:00 pm • Sheraton Phoenix Downtown - Phoenix Ballroom A

This activity is designed to help clinicians bridge key gaps in inflammatory bowel disease (IBD) management. Learners will gain a better understanding of the rapidly evolving IBD therapies and the nuances among agents targeting the same pathway. By the end of this program, participants will be able to choose the most appropriate interleukin (IL)-23 inhibitor for individual patients—whether biologic-naive or biologic-experienced—using objective remission endpoints and patient-reported outcomes and will have honed a patient-centered care approach that incorporates shared decision-making.

Supported by an independent educational grant from Johnson & Johnson.

Breaking News in IBD: Advancing Confidence in Optimizing Subcutaneous Anti-TNF Treatment Across the Care Continuum

Bruce E. Sands, MD, MS, FACG, Aline Charabaty, MD, FACG and Millie D. Long, MD, MPH, FACG
7:00 pm - 8:45 pm • Sheraton Phoenix Downtown - Phoenix Ballroom E

This live event will spotlight the latest evidence on timing, dosing, and safety of anti-TNF therapies. Participants will learn practical, evidence-based recommendations to optimize anti-TNF treatment, personalize switches between agents, and apply novel formulations in moderate to severe Crohn’s disease and ulcerative colitis. By the end of this activity, attendees will feel more confident identifying non-responders, making timely therapeutic adjustments, and integrating anti-TNF strategies into comprehensive patient care.

Supported by an independent educational grant from Celltrion USA, Inc.